Copanlisib for the treatment of adults with relapsed follicular lymphoma-Reference-Cited by-同舟云学术

Copanlisib for the treatment of adults with relapsed follicular lymphoma

Published:2020-07-02 Issue:8 Volume:13 Page:813-823
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Magagnoli Massimo¹,Carlo-Stella Carmelo¹²,Santoro Armando¹²

Affiliation:

1. Department of Oncology and Hematology, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, Italy

2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2020.1787829

Reference62 articles.

1. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: Non-Hodgkin lymphoma. 2017 [cited 2020 Jan 27[th]]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html

2. Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

3. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3

4. Pathogenesis of follicular lymphoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunometabolism in cancer: basic mechanisms and new targeting strategy;Cell Death Discovery;2024-05-16

2. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice;Heliyon;2024-01

3. The Genetic Background of Abnormalities in Metabolic Pathways of Phosphoinositides and Their Linkage with the Myotubular Myopathies, Neurodegenerative Disorders, and Carcinogenesis;Biomolecules;2023-10-19

4. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK);Journal of Enzyme Inhibition and Medicinal Chemistry;2023-07-24

5. Repurposing inhibitors of phosphoinositide 3-kinase as adjuvant therapeutics for bacterial infections;Frontiers in Antibiotics;2023-02-09